^
    No biomarker
    Endometrial Cancer
    pembrolizumab + lenvatinib
    Sensitive
    :
    A1
    Merck (MSD) Press Release - 5d
    MSI-H/dMMR
    Endometrial Cancer
    dostarlimab
    Sensitive
    :
    A1
    AnaptysBio Press Release - 2wk
    CCNE1 overexpression
    Endometrial Cancer
    AZD1775
    Sensitive
    :
    C3
    Clin Cancer Res - 3wk
    HER-2 expression
    Endometrial Adenocarcinoma
    trastuzumab
    Sensitive
    :
    A2
    NTRK1 fusion
    Endometrial Cancer
    entrectinib
    Sensitive
    :
    A2
    NTRK2 fusion
    Endometrial Cancer
    larotrectinib
    Sensitive
    :
    A2
    NTRK3 fusion
    Endometrial Cancer
    larotrectinib
    Sensitive
    :
    A2
    No biomarker
    Endometrial Cancer
    cisplatin + paclitaxel + SGN-15
    Sensitive
    :
    A2
    NTRK1 fusion
    Endometrial Cancer
    larotrectinib
    Sensitive
    :
    A2
    No biomarker
    Endometrial Cancer
    carboplatin + docetaxel
    Sensitive
    :
    A2
    No biomarker
    Endometrial Cancer
    docetaxel
    Sensitive
    :
    A2
    HER-2 positive
    Endometrial Cancer
    trastuzumab
    Sensitive
    :
    A2
    TMB-H
    Endometrial Cancer
    pembrolizumab
    Sensitive
    :
    A2
    No biomarker
    Endometrial Cancer
    cisplatin + ifosfamide
    Sensitive
    :
    A2
    No biomarker
    Endometrial Cancer
    paclitaxel + ifosfamide
    Sensitive
    :
    A2
    No biomarker
    Endometrial Cancer
    ifosfamide
    Sensitive
    :
    A2
    No biomarker
    Endometrial Cancer
    topotecan
    Sensitive
    :
    A2
    No biomarker
    Endometrial Cancer
    albumin-bound paclitaxel
    Sensitive
    :
    A2
    No biomarker
    Endometrial Cancer
    paclitaxel
    Sensitive
    :
    A2
    No biomarker
    Endometrial Cancer
    cisplatin + SGN-15
    Sensitive
    :
    A2
    No biomarker
    Endometrial Cancer
    pegylated liposomal doxorubicin
    Sensitive
    :
    A2
    No biomarker
    Endometrial Cancer
    SGN-15
    Sensitive
    :
    A2
    No biomarker
    Endometrial Cancer
    carboplatin
    Sensitive
    :
    A2
    No biomarker
    Endometrial Cancer
    cisplatin
    Sensitive
    :
    A2
    No biomarker
    Endometrial Cancer
    carboplatin + paclitaxel
    Sensitive
    :
    A2
    No biomarker
    Endometrial Cancer
    temsirolimus
    Sensitive
    :
    A2
    No biomarker
    Endometrial Cancer
    bevacizumab
    Sensitive
    :
    A2
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES